-
1
-
-
0027073276
-
Retinopathy in a population-based study
-
Klein, R. Retinopathy in a population-based study. Trans. Am. Ophthalmol. Soc. 90:561-594, 1992
-
(1992)
Trans. Am. Ophthalmol. Soc.
, vol.90
, pp. 561-594
-
-
Klein, R.1
-
2
-
-
84880235572
-
Major clinical trials of vitreoretinal diseases
-
Regillo, C.D., Brown, G.C., Flyn, H.W., eds. New York: Theme Medical Publishers, Inc.;
-
Chew, E.Y. Major clinical trials of vitreoretinal diseases. In: Regillo, C.D., Brown, G.C., Flyn, H.W., eds. Vitreoretinal Disease, the Essentials. New York: Theme Medical Publishers, Inc.; 1999; p. 667-677.
-
(1999)
Vitreoretinal Disease, the Essentials
, pp. 667-677
-
-
Chew, E.Y.1
-
3
-
-
0025760218
-
Fundus photographic risk factors for progression of diabetic retinopathy
-
Early Treatment Diabetic Retinopathy Study Research Group
-
Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report No. 12. Ophthalmology. 98:823-833,1991
-
(1991)
ETDRS Report No. 12. Ophthalmology.
, vol.98
, pp. 823-833
-
-
-
4
-
-
0028123090
-
Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy
-
Adamis, A.P., Miller, J.W., Bernal, M.T., et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 118:445-450, 1994
-
(1994)
Am. J. Ophthalmol.
, vol.118
, pp. 445-450
-
-
Adamis, A.P.1
Miller, J.W.2
Bernal, M.T.3
-
5
-
-
0027942607
-
Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders
-
Aiello, L.P., Avery, R.L., Arrigg, P.G, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N. Engl. J. Med. 331:1480-1487, 1994
-
(1994)
N. Engl. J. Med.
, vol.331
, pp. 1480-1487
-
-
Aiello, L.P.1
Avery, R.L.2
Arrigg, P.G.3
-
6
-
-
0029018364
-
Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases
-
Pe'er, J., Shweiki D., Itin, A., et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab. Invest. 72:638-645, 1995
-
(1995)
Lab. Invest.
, vol.72
, pp. 638-645
-
-
Pe'Er, J.1
Shweiki, D.2
Itin, A.3
-
7
-
-
23744502535
-
Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6
-
Noma, H., Funatsu, H., Yamasaki, M., et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am. J. Ophthalmol. 140:256-261, 2005
-
(2005)
Am. J. Ophthalmol.
, vol.140
, pp. 256-261
-
-
Noma, H.1
Funatsu, H.2
Yamasaki, M.3
-
8
-
-
27744514210
-
Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy
-
Malik, R.A., Li, C., Aziz, W., et al. Elevated plasma CD105 and vitreous VEGF levels in diabetic retinopathy. J. Cell. Mol. Med. 9:692-697, 2005
-
(2005)
J. Cell. Mol. Med.
, vol.9
, pp. 692-697
-
-
Malik, R.A.1
Li, C.2
Aziz, W.3
-
9
-
-
33646440660
-
Testing intravitreal toxicity of bevacizumab (Avastin)
-
Manzano, R.P.A., Peyman, G.A., Khan, P., et al. Testing intravitreal toxicity of bevacizumab (Avastin). Retina. 26:257- 261, 2006
-
(2006)
Retina.
, vol.26
, pp. 257-261
-
-
Manzano, R.P.A.1
Peyman, G.A.2
Khan, P.3
-
10
-
-
33646464279
-
Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage
-
Spaide, R.F., and Fisher, Y.L. Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina. 26:275-278, 2006
-
(2006)
Retina.
, vol.26
, pp. 275-278
-
-
Spaide, R.F.1
Fisher, Y.L.2
-
11
-
-
33748982649
-
Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy
-
Avery, R.L., Pearlsman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 113:1695-1705, 2006
-
(2006)
Ophthalmology.
, vol.113
, pp. 1695-1705
-
-
Avery, R.L.1
Pearlsman, J.2
Pieramici, D.J.3
-
12
-
-
33749631288
-
Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study)
-
Jorge, R., Costa, R.A., Calucci, D., et al. Intravitreal bevacizumab (Avastin) for persistent new vessels in diabetic retinopathy (IBEPE Study). Retina. 26:1006-1013, 2006
-
(2006)
Retina.
, vol.26
, pp. 1006-1013
-
-
Jorge, R.1
Costa, R.A.2
Calucci, D.3
-
13
-
-
0018372140
-
The third report from the Diabetic Retinopathy Study
-
Diabetic Retinopathy Study Research Group Four risk factors for severe visual loss in diabetic retinopathy
-
Diabetic Retinopathy Study Research Group. Four risk factors for severe visual loss in diabetic retinopathy. The third report from the Diabetic Retinopathy Study. Arch. Ophthalmol. 97:654-655, 1979
-
(1979)
Arch. Ophthalmol.
, vol.97
, pp. 654-655
-
-
-
14
-
-
0029803087
-
Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate
-
Tolentino, M.J., Miller, J.W., Gragoudas, E.S., et al. Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. Ophthalmology. 103:1820-1828, 1996
-
(1996)
Ophthalmology.
, vol.103
, pp. 1820-1828
-
-
Tolentino, M.J.1
Miller, J.W.2
Gragoudas, E.S.3
-
15
-
-
0025892104
-
Early photocoagulation for diabetic retinopathy. ETDRS report number 9
-
Early Treatment Diabetic Retinopathy Study Research Group
-
Early Treatment Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology. 98:766-785, 1991
-
(1991)
Ophthalmology.
, vol.98
, pp. 766-785
-
-
-
16
-
-
0026328280
-
Longterm stability and visual out-come after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation
-
Vander, J.F., Duker, J.S., Benson, W.E., et al. Longterm stability and visual out-come after favourable initial response of proliferative diabetic retinopathy to panretinal photocoagulation. Ophthalmology. 98:1575-1579, 1991
-
(1991)
Ophthalmology.
, vol.98
, pp. 1575-1579
-
-
Vander, J.F.1
Duker, J.S.2
Benson, W.E.3
-
17
-
-
0026759362
-
-
Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study.
-
Flynn, H.W., Jr, Chew, E.Y., Simons, B.D., et al. Pars plana vitrectomy in the Early Treatment Diabetic Retinopathy Study. ETDRS Report No. 17. Ophthalmology. 99:1351-1357, 1992
-
(1992)
ETDRS Report No. 17. Ophthalmology.
, vol.99
, pp. 1351-1357
-
-
Flynn, H.W.1
Chew, E.Y.2
Simons, B.D.3
-
18
-
-
0019980977
-
Single vsmultiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy
-
Doft, B.H., and Blankenship,G.W. Single vsmultiple treatment sessions of argon laser panretinal photocoagulation for proliferative diabetic retinopathy. Ophthalmology. 89:772-779, 1982
-
(1982)
Ophthalmology.
, vol.89
, pp. 772-779
-
-
Doft, B.H.1
Blankenshipg, W.2
-
19
-
-
34247231572
-
Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease
-
Matsumoto, Y., Freund, K.B., Peiretti, E., et al. Rebound macular edema following bevacizumab (Avastin) therapy for retinal venous occlusive disease. Retina. 27:426-431, 2007
-
(2007)
Retina.
, vol.27
, pp. 426-431
-
-
Matsumoto, Y.1
Freund, K.B.2
Peiretti, E.3
-
20
-
-
58249094954
-
Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up
-
Arevalo, J.F., Wu, L., Sanchez, J.G., et al. Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye. 23:117-123, 2009
-
(2009)
Eye.
, vol.23
, pp. 117-123
-
-
Arevalo, J.F.1
Wu, L.2
Sanchez, J.G.3
-
21
-
-
42449094689
-
Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: Results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up
-
Wu, L., Arevalo, J.F., Roca, J.A., et al. Comparison of two doses of intravitreal bevacizumab (Avastin) for treatment of macular edema secondary to branch retinal vein occlusion: results from the Pan-American Collaborative Retina Study Group at 6 months of follow-up. Retina. 28:212-219, 2008
-
(2008)
Retina.
, vol.28
, pp. 212-219
-
-
Wu, L.1
Arevalo, J.F.2
Roca, J.A.3
-
22
-
-
70349150585
-
Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage
-
Huang, Y.H., Yeh, P.T., Chen, M.S., Yang, C.H., and Yang, C.M. Intravitreal bevacizumab and panretinal photocoagulation for proliferative diabetic retinopathy associated with vitreous hemorrhage. Retina. 29:1134-1140,2009
-
(2009)
Retina.
, vol.29
, pp. 1134-1140
-
-
Huang, Y.H.1
Yeh, P.T.2
Chen, M.S.3
Yang, C.H.4
Yang, C.M.5
-
23
-
-
38949099070
-
Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy
-
Arevalo, J.F., Maia, M., Flynn, H.W., Jr., et al. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. Br. J. Ophthalmol. 92:213-216,2008
-
(2008)
Br. J. Ophthalmol.
, vol.92
, pp. 213-216
-
-
Arevalo, J.F.1
Maia, M.2
Flynn Jr., H.W.3
|